Linders, D.G.J.; Deken, M.M.; van Dam, M.A.; Wasser, M.N.J.M.; Voormolen, E.M.C.; Kroep, J.R.; van Dongen, G.A.M.S.; Vugts, D.; Oosterkamp, H.M.; Straver, M.E.;
et al. 89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study. Cancers 2023, 15, 4980.
https://doi.org/10.3390/cancers15204980
AMA Style
Linders DGJ, Deken MM, van Dam MA, Wasser MNJM, Voormolen EMC, Kroep JR, van Dongen GAMS, Vugts D, Oosterkamp HM, Straver ME,
et al. 89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study. Cancers. 2023; 15(20):4980.
https://doi.org/10.3390/cancers15204980
Chicago/Turabian Style
Linders, D. G. J., M. M. Deken, M. A. van Dam, M. N. J. M. Wasser, E. M. C. Voormolen, J. R. Kroep, G. A. M. S. van Dongen, D. Vugts, H. M. Oosterkamp, M. E. Straver,
and et al. 2023. "89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study" Cancers 15, no. 20: 4980.
https://doi.org/10.3390/cancers15204980
APA Style
Linders, D. G. J., Deken, M. M., van Dam, M. A., Wasser, M. N. J. M., Voormolen, E. M. C., Kroep, J. R., van Dongen, G. A. M. S., Vugts, D., Oosterkamp, H. M., Straver, M. E., van de Velde, C. J. H., Cohen, D., Dibbets-Schneider, P., van Velden, F. H. P., Pereira Arias-Bouda, L. M., Vahrmeijer, A. L., Liefers, G. J., de Geus-Oei, L. F., & Hilling, D. E.
(2023). 89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study. Cancers, 15(20), 4980.
https://doi.org/10.3390/cancers15204980
